These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
SARS-CoV-2_paper_04-07-20_chemRxiv.pdf (4.58 MB)

Computational Target-Based Drug Repurposing of Elbasvir, an Antiviral Drug Predicted to Bind Multiple SARS-CoV-2 Proteins

revised on 07.04.2020, 16:49 and posted on 08.04.2020, 10:12 by Meenakshisundaram Balasubramaniam, Robert Shmookler Reis
Coronavirus disease 19 (COVID-19) is a severe acute respiratory syndrome caused by SARS-CoV-2 (2019-nCoV). While no drugs have yet been approved to treat this disease, small molecules effective against other viral infections are under clinical evaluation for therapeutic abatement of SARS-CoV-2 infections. Ongoing clinical trials include Kaletra (a combination of two protease inhibitors approved for HIV treatment), remdesivir (an investigational drug targeting RNA-dependent RNA polymerase [RdRP] of SARS-CoV-2), and hydroxychloroquine (an approved anti-malarial and immuno-modulatory drug). Since SARS-CoV-2 replication depends on three virally encoded proteins (RdRP, papain-like proteinase, and helicase), we screened 54 FDA-approved antiviral drugs and ~3300 investigational drugs for binding to these proteins using targeted and unbiased docking simulations and computational modeling. Elbasvir, a drug approved for treating hepatitis C, is predicted to bind stably and preferentially to all three proteins. At the therapeutic dosage, elbasvir has low toxicity (liver enzymes transiently elevated in 1% of subjects) and well-characterized drug-drug interactions. We predict that treatment with elbasvir, alone or in combination with other drugs such as grazoprevir, could efficiently block SARS-CoV-2 replication. The concerted action of elbasvir on at least three targets essential for viral replication renders viral mutation to drug resistance extremely unlikely.


VA Merit Award 2 I01 BX001655 to RJSR; VA Senior Research Career Scientist Award IK6 BX004851 to RJSR; NIA/NIH Program Project grant P01 AG012411-17A1 to WST Griffin, P.I. (Early Events in Alzheimer Pathogenesis); NIA/NIH research grant AG062254-01 to RJSR and S. Ayyadevara. Inglewood Scholars Program award to MB.


Email Address of Submitting Author


University of Arkansas for Medical Sciences



ORCID For Submitting Author


Declaration of Conflict of Interest

The authors declare no conflicts of interest regarding this manuscript.

Version Notes